Compare Hilton Hotels Corporation Common Stock (HLT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.19 (market cap $72.14B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| HLT | VRTX | |
|---|---|---|
Market Cap | $72.14B | $128.16B |
Volume | 862,817 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $557.96 |
52-Week Low | $256.96 | $407.37 |
Typical Hold Time | 138 Days | 120 Days |
Enterprise Value | $85.15B | $122.29B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $323.29, up 0.21% on the day, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported revenue of $12.04B in 2025, with net income of $1.46B and consistent quarterly EPS beats. Recent news highlights upcoming Q3 2026 earnings and positive travel trends for 2027.
Outlook remains positive with a consensus price target of $348.11, though high debt levels and valuation multiples pose risks. Earnings growth and global expansion in Asia present opportunities, but investors should monitor interest expense and competitive pressures in the hospitality sector.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
